Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive ...

Dr Ryotaro Nakamura - City of Hope, California, USA

17 Feb 2021

Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China

Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China

29 Jan 2021

The Burkitt lymphoma international prognostic index

Prof Adam Olszewski - Brown University, Providence, USA

24 Dec 2020

Results of venetoclax and azacitidine combination in chemotherapy ineligible unt...

Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA

22 Dec 2020

Long-term follow-up of low-intensity chemotherapy with combination therapy for r...

Prof Hagop Kantarjian - MD Anderson Cancer Center, Houston, USA

22 Dec 2020

Real-world evidence of the use of carfilzomib among multiple myeloma patients ac...

Prof Evangelos Terpos - University of Athens, Athens, Greece

22 Dec 2020

Real-world evidence of the use of carfilzomib to refractory to lenalidomide pati...

Prof Evangelos Terpos - University of Athens, Athens, Greece

22 Dec 2020

A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumu...

Prof Evangelos Terpos - University of Athens, Athens, Greece

22 Dec 2020

PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL ...

Dr Liora Schultz - Stanford University School of Medicine, Palo Alto, USA

16 Dec 2020

Researchers trace the origin of blood cancer to early childhood, decades before ...

Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK

16 Dec 2020

ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma

Dr Robert Rifkin, Prof Sagar Lonial, Prof Evangelos Terpos, Dr Nina Shah, Dr Eri...

15 Dec 2020

Survival analysis of newly diagnosed transplant-eligible multiple myeloma patien...

Dr Francesca Gay - University of Torino, Torino, Italy

14 Dec 2020

ETNK1 mutations in atypical chronic myeloid leukaemia can be reverted with phosp...

Dr Diletta Fontana - The University of Milano-Bicocca, Milan, Italy

11 Dec 2020

FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multi...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

10 Dec 2020

Clinical activity and safety of cevostamab in relapsed/refractory multiple myelo...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

10 Dec 2020

ASCEMBL: Asciminib for hard-to-treat chronic myeloid leukaemia

Prof Andreas Hochhaus - Universitätsklinikum Jena, Jena, Germany

10 Dec 2020

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...

Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA

9 Dec 2020

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukae...

Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Nether...

9 Dec 2020

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands

9 Dec 2020

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CL...

Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

9 Dec 2020

Novel bispecific T-cell engager molecule shows promise in r/r multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

9 Dec 2020

ASH 2020: Targeted therapies in r/r multiple myeloma

Prof Marivi Mateos, Prof Meletios Dimopoulos, Prof Meral Beksaç, Dr Shaji Kumar

8 Dec 2020

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy

8 Dec 2020

Decitabine plus ipilimumab in r/r MDS/AML in the post-BMT or transplant naïve se...

Dr Jacqueline Garcia - Dana-Farber Cancer Institute, Boston, USA

8 Dec 2020

Treating acute leukaemias of ambiguous lineage

Dr Lindsey Montefiori - Department of Pathology, St. Jude Children's Research Ho...

8 Dec 2020

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China...

Dr Shaji Kumar and Dr Wenming Chen

8 Dec 2020

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T31...

Dr Jorge Cortes - Augusta University, Augusta, USA

8 Dec 2020

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

8 Dec 2020

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

8 Dec 2020

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil

8 Dec 2020

Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...

Dr Bilal Omer - Baylor College of Medicine, Houston, USA

8 Dec 2020

Blinatumomab and oral TKIs for the treatment of Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

8 Dec 2020

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

8 Dec 2020

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

8 Dec 2020

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany

7 Dec 2020

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

7 Dec 2020

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

7 Dec 2020

Evaluation of MRD negativity in patients with relapsed or refractory multiple my...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

7 Dec 2020

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

7 Dec 2020

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA

7 Dec 2020

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA

7 Dec 2020

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

7 Dec 2020

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

7 Dec 2020

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Trea...

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands

7 Dec 2020

Predictive factors for overall survival in chronic myeloid leukaemia patients: a...

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

6 Dec 2020

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potent...

Prof David Teachey - The University of Pennsylvania, Rutledge, USA

6 Dec 2020

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukae...

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA

5 Dec 2020